ReviewMethods in molecular biology (Clifton, N.J.)2025
Strategy and Application of Viral Potency Assays in Cell and Gene Therapy.
Review in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development and application of robust viral potency assays are critical for ensuring the quality, safety, and efficacy of viral vectors in cell and gene therapy. These assays play pivotal roles in assessing the biological activity of viral products across various stages of development and manufacturing, from early research to clinical use. This review explores key aspects of viral potency assay development, including the genome and physical, infectious, and functional titers, emphasizing their importance in meeting regulatory standards and maintaining product consistency. Additionally, a comprehensive overview of methodologies and protocols for assessing viral potency, with a focus on digital droplet PCR (ddPCR) and flow cytometry-based assays, is provided as examples. Flow-based assays evaluate the functional potency of viral vectors by quantifying transduction efficiency and transgene expression in target cells, highlighting their utility in assessing their biological activity. In addition, ddPCR provides unparalleled sensitivity and accuracy in quantifying viral genome titers, providing absolute measurements critical for quality control and regulatory compliance. Together, these approaches form a robust matrix for potency measurement, enabling the development of high-quality viral vectors that meet stringent regulatory standards. This work serves as a practical guide for researchers and manufacturers, supporting the consistent production and evaluation of viral vectors for clinical applications.
Indexed as
Identifiers
40515915What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.